BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- (Nasdaq:BCRX) today announced that the company will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:30 p.m. ET and the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 1:30 p.m. ET. Both are being conducted as virtual conferences.
Links to a live audio webcast and replay of these presentations may be accessed in the Investors section of BioCryst’s website at .
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States, European Union, Japan and the United Kingdom for the prevention of HAE attacks in adults and pediatric patients 12 years and older. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at .
BCRXW
Investors:
John Bluth
Media:
Catherine Collier Kyroulis
